UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 127

Sortiert nach

Endocrine‐Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management

The oncologist (Dayton, Ohio), 2020-04, Vol.25 (4), p.290-300

2020

Link zum Volltext

Verfügbarkeit prüfen

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e001395

2020

Link zum Volltext

Verfügbarkeit prüfen

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer

Frontiers in oncology, 2021-03, Vol.10, p.581801-581801

2021

Link zum Volltext

Verfügbarkeit prüfen

Relugolix in Clinical Practice: The Best Route for All?

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (8), p.647-650

2023

Link zum Volltext

Verfügbarkeit prüfen

The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?

The lancet oncology, 2021-07, Vol.22 (7), p.915-916

2021

Link zum Volltext

Verfügbarkeit prüfen

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials

The Lancet (British edition), 2022-08, Vol.400 (10351), p.512-521

2022

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules

Clinical cancer research, 2019-08, Vol.25 (16), p.4933-4944

2019

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

The oncologist (Dayton, Ohio), 2020-06, Vol.25 (6), p.479-e899

2020

Link zum Volltext

Verfügbarkeit prüfen

Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute

Journal of clinical oncology, 2022-06, Vol.40 (17), p.1949-1957

2022

Link zum Volltext

Verfügbarkeit prüfen

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide

The oncologist (Dayton, Ohio), 2022-09, Vol.27 (9), p.718-e694

2022

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroids

JAAD Case Reports, 2017-07, Vol.3 (4), p.322-325

2017

Link zum Volltext

Verfügbarkeit prüfen

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single‐Dose Administration Under Fasting Conditions in Prostate Cancer

The oncologist (Dayton, Ohio), 2021-09, Vol.26 (9), p.729-e1493

2021

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors

Cancer chemotherapy and pharmacology, 2020-10, Vol.86 (4), p.475-486

2020

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

Journal for immunotherapy of cancer, 2020-03, Vol.8 (1), p.e000655

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment

Clinical genitourinary cancer, 2020-08, Vol.18 (4), p.258-267.e1

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.116-116

2023

Link zum Volltext

Verfügbarkeit prüfen

Association of 18 F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4600-4600

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of bintrafusp alfa in recurrent/metastatic olfactory neuroblastoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS6116-TPS6116

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2628-2628

2023

Link zum Volltext

Verfügbarkeit prüfen

A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5101-TPS5101

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 127

Suche als RSS-Feed

Aktive Filter

ThemaImmunotherapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(121)
Mit Volltextzugriff
(124)

Publikationsform

Sprache

Englisch
(127)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(49)
Life Sciences & Biomedicine
(40)
Humans
(27)
Oncology
(22)
Male
(15)
Female
(13)
Middle Aged
(12)
Aged
(8)
Prostate Cancer
(8)
Multidisciplinary Sciences
(7)
Science & Technology - Other Topics
(7)
Adult
(6)
Cancer
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(5)
Cancer Research
(5)
Deep Sea
(5)
Metastasis
(5)
Tumors
(5)
Aged, 80 And Over
(4)
Animals
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Endocrine‐Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer

Relugolix in Clinical Practice: The Best Route for All?

The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials

A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide

Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroids

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single‐Dose Administration Under Fasting Conditions in Prostate Cancer

Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment

Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide

Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers

Association of 18 F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies

Phase 2 study of bintrafusp alfa in recurrent/metastatic olfactory neuroblastoma

Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C)

A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL)

Aktive Filter

Suchergebnisse filtern